Nonoperating Income (Expense) in USD of Editas Medicine, Inc. from 2014 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Editas Medicine, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2014 to Q3 2025.
  • Editas Medicine, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2025 was -$569K, a 116% decline year-over-year.
  • Editas Medicine, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2025 was -$988K, a 106% decline year-over-year.
  • Editas Medicine, Inc. annual Nonoperating Income (Expense) for 2024 was $14.1M, a 11.9% decline from 2023.
  • Editas Medicine, Inc. annual Nonoperating Income (Expense) for 2023 was $16M, a 189% increase from 2022.
  • Editas Medicine, Inc. annual Nonoperating Income (Expense) for 2022 was $5.52M, a 757% increase from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)

Editas Medicine, Inc. Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$988K -$569K -$4.09M -116% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-10
Q2 2025 $3.11M -$1.69M -$5.99M -139% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-12
Q1 2025 $9.09M $75K -$4.97M -98.5% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-12
Q4 2024 $14.1M $1.2M -$3.89M -76.5% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-05
Q3 2024 $18M $3.53M -$1.62M -31.5% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-10
Q2 2024 $19.6M $4.3M +$492K +12.9% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-12
Q1 2024 $19.1M $5.04M +$3.12M +162% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-12
Q4 2023 $16M $5.09M +$2.38M +87.9% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-05
Q3 2023 $13.6M $5.14M +$3.35M +187% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-04
Q2 2023 $10.2M $3.8M +$3.02M +387% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $7.21M $1.93M +$1.69M +719% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $5.52M $2.71M +$2.54M +1465% Oct 1, 2022 Dec 31, 2022 10-K 2025-03-05
Q3 2022 $2.98M $1.79M +$1.62M +949% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 $1.36M $781K +$636K +439% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $724K $235K +$80K +51.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-05
Q4 2021 $644K $173K -$3.2M -94.9% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $3.85M $171K +$1.34M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 $2.51M $145K -$7.62M -98.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $10.1M $155K -$8.74M -98.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $18.9M $3.38M +$1.72M +104% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-26
Q3 2020 $17.1M -$1.17M -$2.82M -171% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $20M $7.77M +$5.9M +317% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $14.1M $8.89M +$6.88M +342% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $7.18M $1.65M +$454K +37.9% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-26
Q3 2019 $6.72M $1.65M +$627K +61.5% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-26
Q2 2019 $6.1M $1.86M +$929K +99.5% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-26
Q1 2019 $5.17M $2.01M +$1.39M +225% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-26
Q4 2018 $3.77M $1.2M +$946K +374% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-26
Q3 2018 $2.83M $1.02M +$870K +580% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-26
Q2 2018 $1.96M $934K +$1.26M Apr 1, 2018 Jun 30, 2018 10-K 2020-02-26
Q1 2018 $699K $620K +$1.09M Jan 1, 2018 Mar 31, 2018 10-K 2020-02-26
Q4 2017 -$391K $253K +$645K Oct 1, 2017 Dec 31, 2017 10-K 2019-03-01
Q3 2017 -$1.04M $150K +$5K +3.45% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-01
Q2 2017 -$1.04M -$324K -$482K -305% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-01
Q1 2017 -$559K -$470K -$564K -600% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-01
Q4 2016 $5K -$392K -$132K -50.8% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-08
Q3 2016 $137K $145K +$168K Jul 1, 2016 Sep 30, 2016 10-K 2018-03-08
Q2 2016 -$31K $158K +$37.3M Apr 1, 2016 Jun 30, 2016 10-K 2018-03-08
Q1 2016 -$37.4M $94K +$224K Jan 1, 2016 Mar 31, 2016 10-K 2018-03-08
Q4 2015 -$37.6M -$260K Oct 1, 2015 Dec 31, 2015 10-K 2017-03-03
Q3 2015 -$23K Jul 1, 2015 Sep 30, 2015 10-K 2017-03-03
Q2 2015 -$37.2M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-03
Q1 2015 -$130K Jan 1, 2015 Mar 31, 2015 10-K 2017-03-03

Editas Medicine, Inc. Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $14.1M -$1.9M -11.9% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-05
2023 $16M +$10.4M +189% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-05
2022 $5.52M +$4.87M +757% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-05
2021 $644K -$18.2M -96.6% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 $18.9M +$11.7M +163% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-22
2019 $7.18M +$3.4M +90.2% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
2018 $3.77M +$4.16M Jan 1, 2018 Dec 31, 2018 10-K 2021-02-26
2017 -$391K -$396K -7920% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-26
2016 $5K +$37.6M Jan 1, 2016 Dec 31, 2016 10-K 2019-03-01
2015 -$37.6M -$36.6M -3807% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-08
2014 -$962K Jan 1, 2014 Dec 31, 2014 10-K 2017-03-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.